GSK CFO interviewed on Q1 2012 results
GlaxoSmithKline CFO Simon Dingemans looks at the pharma group's overall Q1 performance plus the impact of the company's new financial architecture, the balance between dividend and share buyback, the drug development pipeline and the outlook for the rest of the year.
Information and opinions contained in this broadcast have been compiled or arrived at by the organisation making this presentation.
This broadcast is hosted, streamed and brought to you by 3B NEXUS who make no representation or warranty regarding the accuracy or reliability or completeness of any information provided and accepts no liability for any loss arising from the use hereof. Any reliance you place on such information will be at your sole risk.
The information, statements and opinions contained in this broadcast do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.
Any statements, information and opinions contained in this broadcast, in particular those concerning investments and the possible or assumed future performance, costs, dividends, returns, production levels or rates, prices, reserves, divestments, growth or other trend projections and any estimated earnings are or may contain certain forward looking statements and as such involve risks and uncertainties.
Actual results and developments may differ materially from those expressed or implied by these statements depending on a variety of factors.